HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of bone scanning in severe frostbite of the extremities: a retrospective study of 88 cases.

Abstract
We performed a retrospective study of the results of two-phase technetium-99m hydroxymethylene diphosphonate bone scans in 88 patients with severe frostbite of the extremities. All patients were evaluated within 48 h after rewarming and all underwent a first bone scan (BS1) within 5 days after rewarming (median, day 2) (group 1). An excellent correlation was found between absence of tracer uptake in the phalanges and later amputation; this correlation was especially strong during the bone phase of the scans (specificity = 0.99, sensitivity = 0.96, positive predictive value = 0.92). Normal or high uptake in the phalanges was a reliable indicator of ultimate healing (negative predictive value = 0.99). The sensitivity of the examination was enhanced by performing a second scan (BS2) more than 5 days (median, day 8) after rewarming (group 2, n = 36). A comparative analysis of BS1 and BS2 demonstrated that some of the lesions continued to evolve between day 2 and day 8. This suggests that the lesions could still be modified during this period. On the basis of the findings it is recommended that bone scan be performed close to day 2 in all patients who present with lesions extending proximally to include the entirety of one or more phalanges. In the case of severe sepsis, the results of the first bone scan, BS1, can serve as an indication for emergency amputation. BS2 should be performed close to day 8 only if there is an area of low or absent uptake on BS1. It is concluded that scintigraphy is an excellent means of evaluating patients with severe frostbite of the extremities: as early as day 2 after the injury it can indicate whether amputation is necessary, and between days 2 and 8 it provides valuable information on the efficacy of treatment.
AuthorsE Cauchy, E Chetaille, M Lefevre, E Kerelou, B Marsigny
JournalEuropean journal of nuclear medicine (Eur J Nucl Med) Vol. 27 Issue 5 Pg. 497-502 (May 2000) ISSN: 0340-6997 [Print] Germany
PMID10853803 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Radiopharmaceuticals
  • technetium Tc 99m hydroxymethylene diphosphonate
  • Technetium Tc 99m Medronate
Topics
  • Adult
  • Bone and Bones (diagnostic imaging)
  • Extremities (diagnostic imaging)
  • Female
  • Foot (diagnostic imaging, pathology)
  • Frostbite (diagnostic imaging, pathology)
  • Hand (diagnostic imaging, pathology)
  • Humans
  • Male
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Retrospective Studies
  • Technetium Tc 99m Medronate (analogs & derivatives)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: